ESALY - Eisai Co., Ltd.
| Previous Close | 75.45 |
| Open | 76.50 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 76.01 - 76.71 |
| 52 Week Range | 48.52 - 89.78 |
| Volume | 14,570 |
| Avg. Volume | 15,611 |
| Market Cap | 20.755B |
| Beta (3Y Monthly) | 0.74 |
| PE Ratio (TTM) | 36.68 |
| EPS (TTM) | 2.08 |
| Earnings Date | N/A |
| Forward Dividend & Yield | 1.47 (1.95%) |
| Ex-Dividend Date | 2019-09-26 |
| 1y Target Est | 90.48 |
- Benzinga
The Daily Biotech Pulse: FDA Nod For Sanofi, BioCryst's Edema Drug In Japan, Myriad's Q1 Disappointment
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 4) Agile Therapeutics Inc (NASDAQ: AGRX )(follow-on rally ...
- Reuters
Biogen, Eisai revive plans for Alzheimer's drug, surprising market
Shares in Eisai Co , Biogen's Japanese partner in the drug, were quoted up 18% to the daily limit high of 6,534 yen in Tokyo trading. The field of experimental Alzheimer's treatments is littered with high-profile failures, with many major drugmakers abandoning the race to develop a medicine for a disease that makes up 60%-70% of an estimated 50 million dementia cases globally. Any medicine that effectively treats the disease is likely to become one of the world's top-selling drugs and could be transformative for Biogen, which is facing multiple challenges over its product pipeline.
- Benzinga
Biogen Plans Filing For Failed Alzheimer's Drug After New Analysis
The stock fell under the psychological barrier of $300 March 21, when the company and its development partner Eisai Co., Ltd (OTC: ESALY) announced their decision to shelve two late-stage studies dubbed ENGAGE and EMERGE that evaluated the efficacy and safety of aducanumab in patients with mild cognitive impairment due to Alzheimer's disease and mild Alzheimer's disease dementia. Biogen said Tuesday it plans to file a BLA for aducanumab for the treatment of early Alzheimer's disease following consultation with the FDA.
- MarketWatch
Biogen says it will pursue FDA approval of early Alzheimer's drug
Biogen said it will pursue regulatory approval for aducanumab, an investigational treatment for early Alzheimer's disease after consulting with the U.S. Food and Drug Administration. A Phase 3 trial met its primary endpoint showing a significant reduction in clinical decline, and Biogen believes that results from a subset of patients in the study who received sufficient exposure to high dose aducanumab support the finding. The decision to file is based on a new analysis, conducted by Biogen in consultation with the FDA, of a larger dataset from the Phase 3 clinical studies that were discontinued in March 2019 following a futility analysis.
- Barrons.com
Merck Won ‘Groundbreaking’ Approval for Cancer Treatment in 3 Countries at Once
The U.S., Australia, and Canada will allow Merck’s Keytruda to be used together with a drug developed by Japan’s Eisai to treat some forms of advanced endometrial carcinoma.
- Investor's Business Daily
Biogen Scraps 2 More Studies In Alzheimer's Disease — And Shares Pop
Biogen stock popped in relief Friday after the biotech company scrapped several tests in Alzheimer's treatment for a drug known as elenbecestat. It was being developed with Japan's Eisai.
- Reuters
UPDATE 2-Biogen scraps two late-stage trials for Alzheimer's treatment
Biogen Inc and Eisai Co Ltd are abandoning two late-stage trials for their Alzheimer's treatment in a widely anticipated move that comes months after the companies scrapped trials of another drug for the memory-robbing disease. The companies said on Friday the decision was based on the results of a review conducted by a data safety monitoring board, which recommended discontinuing the trials as benefits from the treatment, elenbecestat, did not outweigh its risks. Shares of Biogen were up 2.3% at $237.60 as some analysts said ending the trial would save the company costs associated with running it through its completion.
- MarketWatch
Biogen's stock falls after co. and Eisai to discontinue late-stage trial of Alzheimer's treatment
Shares of Biogen Inc. fell 1.6% in premarket trading Friday, after the the biotechnology company and Tokyo-based Eisai Co. Ltd. said they will discontinue the phase 3 trial of an Alzheimer's disease (AD) treatment, citing data showing an unfavorable risk-benefit ratio. The decision was made after the Data Safety Monitoring Board's recommendation to discontinue the trials. The trial on the investigational oral beta amyloid cleaving enyzme (BACE) inhibitor elenbecestat in patients with early AD. The companies said as part of the decision to discontinue the phase 3 trial, the long-term extension of the phase 2 trial of elenbecestat will also be discontinued. Biogen's stock has dropped 22.8% year to date through Thursday and the U.S.-listed shares of Eisai have tumbled 34.6%, while the S&P 500 has gained 20.1%.
- TheStreet.com
Biogen Rises After Canceling Two Late-Stage Alzheimer's Trials
Results of a safety review convinces Biogen to shut down the trials of its experimental Alzheimer's treatment.
- Benzinga
Eisai's Cancer Drug Combo Gets Breakthrough Therapy Designation For Liver Cancer
Japanese drug maker Eisai Co., Ltd (OTC: ESALY ) has some positive news concerning one of its pipeline candidates. What Happened Eisai said the FDA has granted Breakthrough Therapy Designation for Lenvima, ...
- Benzinga
The Daily Biotech Pulse: Acadia Schizophrenia Drug Fails, Viveve Plummets, Eisai Gets Breakthrough Therapy Designation
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on July 22) Acasti Pharma Inc (NASDAQ: ACST ) Apellis Pharmaceuticals ...
- TheStreet.com
Watch These 4 Japanese Drugmakers With Big Coming Events
Investors should keep tabs on these "focus events" from this quartet of U.S.-listed Japanese drugmakers that can make or break their treatments.
- Zacks
Xencor (XNCR) Jumps: Stock Rises 7.4%
Xencor (XNCR) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
- Zacks
The Zacks Analyst Blog Highlights: Eisai, Martin Marietta and Columbia Sportswear
The Zacks Analyst Blog Highlights: Eisai, Martin Marietta and Columbia Sportswear
- Zacks
Ocular (OCUL) Gets FDA Nod for Label Expansion of Dextenza
Ocular (OCUL) clinches the FDA approval for the label expansion of Dextenza to treat ocular inflammation following ophthalmic surgery.
- Investor's Business Daily
Why Alzheimer's Treatment Hopes Endure Despite High-Profile Drug Failures
Alzheimer's treatment continues to confound biotech companies in the wake of Biogen and Eisai's decision to terminate two late-stage tests. But scientists say there's hope in new theories.
- Zacks
Ocular's Glaucoma Drug Study Fails to Meet Primary Endpoint
Ocular's (OCUL) phase III study on OTX-TP for the reduction of intraocular pressure (IOP) in patients with primary open-angle glaucoma fails to achieve primary endpoint.
- Zacks
Catalent Acquires Gene Therapy Leader Paragon Bioservices
Catalent (CTLT) acquires gene therapy leader Paragon Bioservices for $1.2 billion.
Market RealistKey Drugs in Merck’s Oncology Portfolio
Comparing MRK’s and ABBV’s Outlook: Which Is the Better Pick?(Continued from Prior Part)Lenvima growth trendsIn the first quarter, Merck’s (MRK) and Eisai’s Lenvima reported solid uptake across multiple markets, driven mainly by demand in
- Zacks
CannTrust Holdings (CTST) in Focus: Stock Moves 6.1% Higher
CannTrust Holdings (CTST) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
- Zacks
Catalyst (CPRX) Q1 Loss Narrows, Firdapse Off to a Good Start
Catalyst (CPRX) posts narrower-than-expected loss and beats on revenues in the first quarter of 2019.
- Zacks
Zoetis (ZTS) Earnings Beat Estimates in Q1, Revenues Miss
Zoetis???s (ZTS) earnings beat estimates but sales miss the same in the first quarter of 2019.
- Benzinga
The Daily Biotech Pulse: Nabriva Stumbles At FDA Hurdle, Gilead CFO To Retire, Eisai Ends Collaboration With Purdue
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on April 30) VolitionRX Ltd (NYSE: VNRX ) ZEALAND PHARMA/S ADR ...
